Literature DB >> 22179055

Therapeutic drug monitoring in the treatment of tuberculosis patients.

Cecile Magis-Escurra1, Jossy van den Boogaard, Dirk Ijdema, Martin Boeree, Rob Aarnoutse.   

Abstract

At the University Centre for Chronic Diseases Dekkerswald, a tertiary tuberculosis (TB) referral hospital in The Netherlands, therapeutic drug monitoring (TDM) is used in patients in case of relapse TB, when there is delayed response to TB treatment, and when abnormal TB drug concentrations are suspected for other reasons. In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations. Increased doses of the TB drugs, especially of rifampicin, resulted in adequate peak plasma concentrations and improved clinical response to treatment in these patients, while no adverse events occurred. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179055     DOI: 10.1016/j.pupt.2011.12.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  21 in total

1.  Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Authors:  Abdullah Alsultan; Guohua An; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs.

Authors:  Ilaria Motta; Andrea Calcagno; Lorena Baietto; Paolo Bigliano; Cecilia Costa; Katia Baruffi; Giovanna Fatiguso; Antonio D'Avolio; Giovanni Di Perri; Stefano Bonora
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

3.  Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.

Authors:  Stijn W van Beek; Rob Ter Heine; Ron J Keizer; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 5.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

6.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.

Authors:  Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Seong Mi Moon; Su-Young Kim; Soo-Youn Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 7.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

8.  Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Authors:  Sampson Antwi; Hongmei Yang; Anthony Enimil; Anima M Sarfo; Fizza S Gillani; Daniel Ansong; Albert Dompreh; Antoinette Orstin; Theresa Opoku; Dennis Bosomtwe; Lubbe Wiesner; Jennifer Norman; Charles A Peloquin; Awewura Kwara
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

9.  Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.

Authors:  Amélie Marsot; Amelie Ménard; Julien Dupouey; Cedric Muziotti; Romain Guilhaumou; Olivier Blin
Journal:  Br J Clin Pharmacol       Date:  2017-01-16       Impact factor: 4.335

Review 10.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.